Joint Pain News and Research RSS Feed - Joint Pain News and Research

Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. [More]
Smartphones, tablets can do damage to overall health in unexpected ways

Smartphones, tablets can do damage to overall health in unexpected ways

Despite the many benefits of having information at your fingertips, smartphones and tablets can do damage to your body and overall health in unexpected ways. [More]
New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

A new Duke-NUS-led study has identified a super-potent antibody which requires a minute amount to neutralize the dengue virus. [More]
UT Southwestern researchers identify common signaling mechanism that controls immune system

UT Southwestern researchers identify common signaling mechanism that controls immune system

UT Southwestern Medical Center researchers have identified a common signaling mechanism to produce interferon - one of the main proteins used to signal the immune system when the body needs to defend itself against a virus, tumor, or other diseases. [More]
TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

Continuing its efforts to fight for settlements that are fair to consumers and mandate real changes in deceptive marketing, advocacy group truthinadvertising.org (TINA.org) has filed an objection in a proposed class-action settlement involving the brand-name glucosamine supplement, Wellesse®. Sold at retailers nationwide, the supplement is advertised as a joint pain remedy to ease pain and even rebuild cartilage. [More]
DePuy Synthes announces acquisition of Olive Medical

DePuy Synthes announces acquisition of Olive Medical

Today DePuy Synthes Companies announced that it has acquired Olive Medical Corporation, a Utah-based privately held provider of high definition (HD) visualization systems for minimally invasive surgery (MIS). Financial terms of the transaction were not disclosed. [More]
Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism. [More]
Study: Lyme disease costs the U.S. health care system up to $1.3 billion a year

Study: Lyme disease costs the U.S. health care system up to $1.3 billion a year

Lyme disease, transmitted by a bite from a tick infected by the Borrelia burgdorferi bacteria, had long been considered easy to treat, usually requiring a single doctor's visit and a few weeks of antibiotics for most people. [More]
News study finds association between chronic fatigue syndrome and early menopause

News study finds association between chronic fatigue syndrome and early menopause

A newfound link between chronic fatigue syndrome (CFS) and early menopause was reported online today in Menopause, the journal of The North American Menopause Society. [More]
Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

A mosquito-borne virus that has spread to the Caribbean and Central and South America and has caused isolated infections in Florida often causes joint pain and swelling similar to that seen in patients with rheumatoid arthritis. [More]
Gluten-free diet important for people with celiac disease

Gluten-free diet important for people with celiac disease

You'd never suspect it from the proliferation of gluten-free items on supermarket shelves. Yet only one in approximately 133 people - that's 0.75 percent of the population - has celiac disease, a genetic autoimmune disorder that causes the body to react negatively to the intake of gluten, a protein found in wheat, rye, barley and their derivatives. [More]
Alzheimer's drug Aricept (donepezil) linked to serious side effects

Alzheimer's drug Aricept (donepezil) linked to serious side effects

New warnings have been added to the prescribing information for the Alzheimer's drug Aricept (donepezil) advising of the risk of two rare but potentially serious conditions: muscle breakdown (rhabdomyolysis) and a neurological disorder called neuroleptic malignant syndrome (NMS). [More]
AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

AVACEN Medical announced today that it has launched a $2 million campaign on Crowdfunder.com to support further company clinical trials and FDA applications. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

It may seem counterintuitive, but exercise can be beneficial for people suffering from arthritis and other muscle and joint conditions. A new study at Hospital for Special Surgery finds that older adults experienced less pain, reduced stiffness and less fatigue after participating in a hospital-based exercise program. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Gout attacks are most common at night

Gout attacks are most common at night

Research, published today, has shown that an acute gout attack is more than twice as likely to occur during the night or early morning hours as during the day. The increased prevalence of gout attacks at night time was observed even after 24 hours with no alcohol and low purine intake. [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program. [More]
National Psoriasis Foundation to hold free psoriatic arthritis program in Dallas-Fort Worth area

National Psoriasis Foundation to hold free psoriatic arthritis program in Dallas-Fort Worth area

If you're one of the roughly 48,000 Dallas-Fort Worth area residents struggling with pain from psoriatic arthritis (PsA)—an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons—learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation, at the Dallas Marriott Las Colinas on December 6. [More]